Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olaparib

FDA-approved product (capsule, oral), marketed as Lynparza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Olaparib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
FDA pharmacologic class
Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olaparib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

    NCT04753879 · start 2021-09-29

    Registered record
    Registry ID
    NCT04753879
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    Nab-paclitaxel; Gemcitabine; Cisplatin; Irinotecan; Capecitabine; Pembrolizumab; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-09-29
    Completion
    2026-07-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionNab-paclitaxel; Gemcitabine; Cisplatin; Irinotecan +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

    NCT05245994 · start 2021-08-21

    Registered record
    Registry ID
    NCT05245994
    Conditions
    Lung Cancer; Small Cell Lung Cancer; Durvalumab
    Interventions
    Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-08-21
    Completion
    2023-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Small Cell Lung Cancer; Durvalumab
    InterventionDurvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
    PhasePhase 2
    Registry statusUnknown

  • Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

    NCT04643379 · start 2021-08-07

    Registered record
    Registry ID
    NCT04643379
    Conditions
    Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma
    Interventions
    Olaparib; Pembrolizumab; Carboplatin; Peripheral blood draw
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-07
    Completion
    2028-10-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma
    InterventionOlaparib; Pembrolizumab; Carboplatin; Peripheral blood draw
    PhasePhase 2
    Registry statusActive not recruiting

  • Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

    NCT04560452 · start 2021-03-15

    Registered record
    Registry ID
    NCT04560452
    Conditions
    Ovarian Cancer; Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-15
    Completion
    2025-09-05
    Enrolment
    1,018

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Prostate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Olaparib in Patients With HRD Malignant Mesothelioma

    NCT04515836 · start 2021-02-19

    Registered record
    Registry ID
    NCT04515836
    Conditions
    Mesothelioma; Homologous Recombination Deficiency
    Interventions
    Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-19
    Completion
    2028-04-15
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMesothelioma; Homologous Recombination Deficiency
    InterventionOlaparib
    PhasePhase 2
    Registry statusRecruiting

  • Olaparib With Ceralasertib in Recurrent Osteosarcoma

    NCT04417062 · start 2020-11-24

    Registered record
    Registry ID
    NCT04417062
    Conditions
    Osteosarcoma; Osteosarcoma Recurrent
    Interventions
    Olaparib; Ceralasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-24
    Completion
    2026-12-01
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteosarcoma; Osteosarcoma Recurrent
    InterventionOlaparib; Ceralasertib
    PhasePhase 2
    Registry statusActive not recruiting

  • Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

    NCT04209686 · start 2020-07-31

    Registered record
    Registry ID
    NCT04209686
    Conditions
    Advanced Gastric Adenocarcinoma
    Interventions
    Paclitaxel; Olaparib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-31
    Completion
    2025-11-17
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Adenocarcinoma
    InterventionPaclitaxel; Olaparib; Pembrolizumab
    PhasePhase 2
    Registry statusCompleted

  • Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

    NCT04042831 · start 2020-06-24

    Registered record
    Registry ID
    NCT04042831
    Conditions
    Bile Duct Adenocarcinoma; Fanconi Anemia Complementation Group Gene Mutation; Metastatic Bile Duct Carcinoma; PTEN Gene Deletion
    Interventions
    Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-06-24
    Completion
    2026-08-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Duct Adenocarcinoma; Fanconi Anemia Complementation Group Gene Mutation; Metastatic Bile Duct Carcinoma; PTEN Gene Deletion
    InterventionBiospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib
    PhasePhase 2
    Registry statusActive not recruiting

  • TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

    NCT04166435 · start 2020-06-17

    Registered record
    Registry ID
    NCT04166435
    Conditions
    Colorectal Cancer
    Interventions
    Temozolomide + Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-06-17
    Completion
    2023-06-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionTemozolomide + Olaparib
    PhasePhase 2
    Registry statusCompleted

  • Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

    NCT03838744 · start 2020-05-20

    Registered record
    Registry ID
    NCT03838744
    Conditions
    Advanced Soft Tissue Sarcoma
    Interventions
    Standard arm: Trabectedin in monotherapy; Experimental arm: Trabectedin + Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-20
    Completion
    2024-11-29
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft Tissue Sarcoma
    InterventionStandard arm: Trabectedin in monotherapy; Experimental arm: Trabectedin + Olaparib
    PhasePhase 2
    Registry statusCompleted

  • Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

    NCT04269200 · start 2020-05-05

    Registered record
    Registry ID
    NCT04269200
    Conditions
    Endometrial Neoplasms
    Interventions
    olaparib; durvalumab; durvalumab placebo; olaparib placebo; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-05-05
    Completion
    2027-04-01
    Enrolment
    805

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Neoplasms
    Interventionolaparib; durvalumab; durvalumab placebo; olaparib placebo +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

    NCT04123366 · start 2019-11-18

    Registered record
    Registry ID
    NCT04123366
    Conditions
    Solid Tumors
    Interventions
    Olaparib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-18
    Completion
    2026-06-08
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionOlaparib; Pembrolizumab
    PhasePhase 2
    Registry statusCompleted

  • Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

    NCT03951415 · start 2019-07-08

    Registered record
    Registry ID
    NCT03951415
    Conditions
    Endometrial Neoplasms; Uterine Neoplasms; Endometrium Cancer
    Interventions
    PARP inhibitor and Anti-PD-L1
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-07-08
    Completion
    2021-08-01
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Neoplasms; Uterine Neoplasms; Endometrium Cancer
    InterventionPARP inhibitor and Anti-PD-L1
    PhasePhase 2
    Registry statusUnknown

  • Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

    NCT03976323 · start 2019-06-28

    Registered record
    Registry ID
    NCT03976323
    Conditions
    Carcinoma, Nonsquamous Non-small-cell Lung
    Interventions
    Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-28
    Completion
    2026-01-29
    Enrolment
    1,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Nonsquamous Non-small-cell Lung
    InterventionPembrolizumab; Pemetrexed; Carboplatin; Cisplatin +1 more
    PhasePhase 3
    Registry statusCompleted

  • Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

    NCT03931551 · start 2019-04-30

    Registered record
    Registry ID
    NCT03931551
    Conditions
    Advanced Breast Cancer
    Interventions
    Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-04-30
    Completion
    2022-03-02
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionOlaparib [Lynparza®] plus Trastuzumab [Herceptin®]
    PhasePhase 2
    Registry statusTerminated